Quest Diagnostics Incorporated
174.78-3.50 (-1.96%)
Oct 29, 4:00:02 PM EDT · NYSE · DGX · USD
Key Stats
Market Cap
19.44BP/E (TTM)
20.54Basic EPS (TTM)
8.51Dividend Yield
0.02%Recent Filings
8-K
Q3 revenues up 13.1%
Quest Diagnostics posted third-quarter revenues of $2.82 billion, up 13.1% year-over-year, with adjusted diluted EPS rising 13.0% to $2.60 amid robust organic growth and acquisitions. The company inked a joint venture with Corewell Health for Michigan lab services, projecting $1 billion in Co-Lab Solutions revenues next year. Revenues soared. Full-year 2025 adjusted EPS guidance climbed to $9.76-$9.84, yet economic volatility poses risks.
10-Q
Q3 FY2025 results
Quest Diagnostics posted solid Q3 results, with net revenues climbing 13.1% year-over-year to $2,816 million, fueled by 12.5% requisition volume growth (3.9% organic) and 0.8% revenue per requisition rise, while operating income rose 16.8% to $386 million on gross margins expanding to 33.7% from productivity gains via the Invigorate program. Diluted EPS hit $2.16, up 8.5% year-over-year, aligning with 113 million diluted shares and no anti-dilution flags. Acquisitions like LifeLabs (closed August 2024 for ~$1 billion cash) and Spectra assets (August 2025 for $34 million cash, recognizing $25 million goodwill and $9 million intangibles over 15 years) drove volume, alongside $51 million in YTD acquisitions; free cash flow stood at $1,052 million (derived from $1,421 million operating cash minus $369 million capex). Cash dipped to $432 million, total debt fell to $5,675 million (fair value $5.7 billion), with $1.3 billion credit availability and no covenant issues. Yet regulatory shifts from the OBBBA could trim revenues by up to 50-60 basis points through 2028.
10-Q
Q2 FY2025 results
Quest Diagnostics posted solid Q2 FY2025 results, with net revenues up 15.2% y/y to $2,761M, driven by 10.3% from recent acquisitions like LifeLabs and 2.1% organic volume growth, while revenue per requisition dipped 0.4% y/y (derived) due to LifeLabs' lower mix but rose 3.3% organically from more tests per requisition. Operating income climbed 23.3% y/y to $438M, lifting the margin to 15.9% from 14.8%, thanks to Invigorate program efficiencies offsetting wage and supply costs. Diluted EPS grew 21.7% y/y to $2.47, reconciling to net income of $282M over 113M shares. Cash from operations hit $858M YTD, down from $549M at year-end, with $319M on hand; total debt fell to $5,673M after repaying $600M notes, and the $750M revolver remains undrawn. LifeLabs closed in August 2024 for ~$1B cash, adding $27M goodwill. Yet regulatory scrutiny in healthcare billing lingers.
8-K
Quest boosts Q2 revenue 15.2%
Quest Diagnostics posted Q2 2025 revenues of $2.76 billion, surging 15.2% year-over-year, fueled by 5.2% organic growth, acquisitions, and robust demand for clinical solutions. Adjusted diluted EPS climbed 11.5% to $2.62, backed by productivity gains from automation. Revenues beat expectations; full-year guidance now projects $10.80-$10.92 billion in sales and adjusted EPS of $9.63-$9.83. Strong cash flow hit $858 million year-to-date, up 67.1%. Momentum builds.
8-K
Quest elects directors, approves comp
Quest Diagnostics held its 2025 Annual Meeting on May 15, electing all ten director nominees, including Robert B. Carter and James E. Davis, with strong support exceeding 90% for most amid 8.2 million broker non-votes. Stockholders approved executive compensation by 85.9 million for votes and ratified PricewaterhouseCoopers as auditors with 95.6 million yeses. A proposal for special stockholder meetings failed decisively, 9.5 million to 84.4 million. Governance continuity holds firm.
IPO
Employees
Sector
Industry
DHR
Danaher Corporation
214.01-2.89
IDXG
Interpace Biosciences, Inc.
1.10-0.04
IDXX
IDEXX Laboratories, Inc.
627.66-6.70
ILMN
Illumina, Inc.
95.03-2.77
IQV
IQVIA Holdings, Inc.
217.83-0.30
LH
Labcorp Holdings Inc.
248.14-11.55
MEHCQ
23andMe Holding Co.
3.50+0.00
NEO
NeoGenomics, Inc.
10.28+0.36
QGEN
Qiagen N.V.
47.19-0.76
WGS
GeneDx Holdings Corp.
131.76-5.71